Advances in the prevention and treatment of lung cancer

Lung cancer remains the most common fatal malignancy in the Western world. Survival rates have only improved modestly over the past three decades and new approaches are urgently required. It is clear that a concerted effort to reduce cigarette smoking is required. However, about 10% of patients with lung cancer are never smokers, indicating genetic or other predisposition. Lung cancer screening programmes are being trialled to target high-risk populations. Genetic strategies will provide new methods for screening and

Molecular imaging of the atherosclerotic plaque using positron emission tomography

Accurately assessing an individual’s risk of myocardial infarction or stroke using currently available risk stratification tools remains a challenge, even in patients with symptomatic disease. Inflammation, micro-calcification and intra-plaque angiogenesis occur during the development and ultimate rupture of vulnerable plaques. Molecular imaging techniques such as combined positron emission tomography and computed tomography (PET/CT) offer the opportunity to target these key cellular processes within atheroma and identify high-risk lesions. In this

Interpretation of the full blood count in systemic disease – a guide for the physician

The full blood count (FBC) is perhaps the single most common investigation performed in medical patients. It has the potential, when interpreted carefully and in relation to the clinical history, to provide very useful information to assist in diagnosis and management. Clinicians are often alerted to the presence of a primary haematological disorder by abnormalities in the FBC. For the purpose of this review these diseases will not be discussed in detail but the reader will be alerted to pointers which might indicate primary blood disorders throughout the text.

Advances in the prevention and treatment of lung cancer

Lung cancer remains the most common fatal malignancy in the Western world. Survival rates have only improved modestly over the past three decades and new approaches are urgently required. It is clear that a concerted effort to reduce cigarette smoking is required. However, about 10% of patients with lung cancer are never smokers, indicating genetic or other predisposition. Lung cancer screening programmes are being trialled to target high-risk populations. Genetic strategies will provide new methods for screening and predicting response to treatment.